Comparison of Rivaroxaban and Enoxaparin to Prevent Deep Vein Thrombosis

Comparison of Rivaroxaban and Enoxaparin to Prevent Deep Vein Thrombosis in Patients with Pelvic Fracture

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190120042419N1

Enrollment

112

Registered

2019-02-09

Start date

2019-01-24

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Fracture. Multiple fractures of lumbar spine and pelvis

Interventions

Intervention 1: Intervention group: A dose of 10 milligrams Rivaroxaban will be giving orally once a day for two weeks. Intervention 2: Control group: Enoxaparin will be giving at a dose of 40 milligr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Pelvic Fracture No need for surgery

Exclusion criteria

Exclusion criteria: Having kidney disease Use of anticoagulation drugs in less than a week Being pregnant Being in duration of breastfeeding Liver disease Having a head trauma

Design outcomes

Primary

Measure	Time frame
Deep Vein Thrombosis. Timepoint: Two times from the beginning of the study to distance two weeks. Method of measurement: Having any signs of pain in the leg.	—

Secondary

Measure	Time frame
Bleeding. Timepoint: Two times from the beginning of the study to distance two weeks. Method of measurement: Any type of abnormal bleeding will be recorded in the during the study.;Cost of intervention consumption. Timepoint: Deal of Drug consumption in during treatment. Method of measurement: Mean of consumption cost.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPeyman Hafezimoghadam

Iran University of Medical Sciences

hafezimoghadam@yahoo.com+98 21 6652 5327

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026